Plain-English translation of NCT06417736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether megestrol acetate combined with a membrane-inhibiting formula can effectively treat early-stage uterine cancer and pre-cancerous uterine conditions in women aged 18–45 who want to have children. The study will examine whether adding this medication to standard treatment helps patients recover faster, what side effects occur, and whether patients can become pregnant afterward. Researchers will track your progress every three months for six months.
Young women with early-stage uterine cancer face a difficult choice: standard treatment often requires removing the uterus, which ends any chance of having biological children. This trial is exploring whether this medication combination might control the cancer or pre-cancerous growth while letting women keep their uterus and their fertility.
You likely qualify if…
You likely don't qualify if…
You will take two medications by mouth every day for 24 weeks (about 6 months): megestrol acetate and a membrane-inhibiting formula. You will visit the clinic once every three months for check-ups, blood tests, and a procedure where doctors examine the inside of your uterus with a small camera. You will also keep a diary of your test results and any findings from your pathology reports.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China